Join us for a virtual R&D Day with ASLAN Pharmaceuticals, featuring Key Opinion Leader (KOL) Brett King MD PhD (Yale University School of Medicine) who will discuss the unmet medical need and current limited treatments for patients suffering from alopecia areata (AA), a common autoimmune disease driven by loss of immune privilege (IP) in the hair follicles and subsequent attack by interferon gamma (IFNγ)-secreting immune cells, resulting in complete or partial hair loss on the scalp and body.

The ASLAN leadership team will then provide an update on its clinical program to investigate farudodstat, a novel, oral inhibitor of dihydroorotate dehydrogenase (DHODH), in a Phase 2 proof-of-concept trial, as a potential first-in-class treatment for AA. Farudodstat has been shown to inhibit IFNγ secretion, reduce immune cell proliferation, and potentially protect hair follicles from IP collapse in a human AA disease model.

A live question and answer session will follow the formal presentations.